GenEdit and Genentech Partner for the Discovery and Development of Novel Nanoparticles to Treat Autoimmune Diseases
Shots:
- GenEdit and Genentech have signed a multiyear collaboration and license agreement for the discovery and development of hydrophilic nanoparticles (HNPs) to design nucleic acid-based therapies for autoimmune diseases by utilizing the former’s NanoGalaxy platform
- As per the agreement, preclinical, clinical, regulatory development and commercialization of products resulting from the use of GenEdit’s nanoparticles will be carried out by Genentech
- Furthermore, GenEdit will be eligible to receive $15M as an upfront payment and near-term, preclinical, clinical development, commercial & net sales milestone payments of up to $629M along with tiered royalties on net global sales
Ref: GenEdit | Image: Genentech
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
